Cabaletta Bio (CABA) Common Equity (2018 - 2025)

Cabaletta Bio's Common Equity history runs 8 years deep, the most recent figure standing at $112.1 million for Q4 2025.

• On a quarterly basis, Common Equity fell 26.44% year-over-year to $112.1 million in Q4 2025; TTM through Dec 2025 was $112.1 million, a 26.44% decrease from a year earlier, with the FY2025 full-year figure at $112.1 million, down 26.44% from the prior year.
• Common Equity eased to $112.1 million in Q4 2025 per CABA's latest filing, from $139.5 million in the prior quarter.
• Across five years, Common Equity topped out at $236.2 million in Q4 2023 and bottomed at $85.9 million in Q3 2022.
• The 5-year median for Common Equity is $119.8 million (2021), against an average of $139.7 million.
• Across the five-year window, Common Equity soared 141.92% in 2024 and sank 45.18% in 2025, its largest moves.
• Year by year, Common Equity stood at $118.0 million in 2021, then decreased by 11.39% to $104.5 million in 2022, then jumped by 125.98% to $236.2 million in 2023, then slumped by 35.51% to $152.3 million in 2024, then slipped by 26.44% to $112.1 million in 2025.
• Per Business Quant, the three latest CABA Common Equity figures stand at $112.1 million (Q4 2025), $139.5 million (Q3 2025), and $178.5 million (Q2 2025).